Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature

Allergic bronchopulmonary aspergillosis (ABPA) has been documented in 5% to 10% of patients with oral corticosteroid (OCS)-dependent asthma.1 Oral itraconazole,2 aerosolized amphotericin B,3,4 and omalizumab5 have been proposed as steroid-sparing options. However, these treatments have limited documented efficacy, and adverse effects may limit therapy. Itraconazole is efficient in less than 50%…